-
Coupling streaming AI and HPC ensembles to achieve 100-1000x faster biomolecular simulations
Authors:
Alexander Brace,
Igor Yakushin,
Heng Ma,
Anda Trifan,
Todd Munson,
Ian Foster,
Arvind Ramanathan,
Hyungro Lee,
Matteo Turilli,
Shantenu Jha
Abstract:
Machine learning (ML)-based steering can improve the performance of ensemble-based simulations by allowing for online selection of more scientifically meaningful computations. We present DeepDriveMD, a framework for ML-driven steering of scientific simulations that we have used to achieve orders-of-magnitude improvements in molecular dynamics (MD) performance via effective coupling of ML and HPC o…
▽ More
Machine learning (ML)-based steering can improve the performance of ensemble-based simulations by allowing for online selection of more scientifically meaningful computations. We present DeepDriveMD, a framework for ML-driven steering of scientific simulations that we have used to achieve orders-of-magnitude improvements in molecular dynamics (MD) performance via effective coupling of ML and HPC on large parallel computers. We discuss the design of DeepDriveMD and characterize its performance. We demonstrate that DeepDriveMD can achieve between 100-1000x acceleration for protein folding simulations relative to other methods, as measured by the amount of simulated time performed, while covering the same conformational landscape as quantified by the states sampled during a simulation. Experiments are performed on leadership-class platforms on up to 1020 nodes. The results establish DeepDriveMD as a high-performance framework for ML-driven HPC simulation scenarios, that supports diverse MD simulation and ML back-ends, and which enables new scientific insights by improving the length and time scales accessible with current computing capacity.
△ Less
Submitted 12 July, 2022; v1 submitted 10 April, 2021;
originally announced April 2021.
-
Pandemic Drugs at Pandemic Speed: Infrastructure for Accelerating COVID-19 Drug Discovery with Hybrid Machine Learning- and Physics-based Simulations on High Performance Computers
Authors:
Agastya P. Bhati,
Shunzhou Wan,
Dario Alfè,
Austin R. Clyde,
Mathis Bode,
Li Tan,
Mikhail Titov,
Andre Merzky,
Matteo Turilli,
Shantenu Jha,
Roger R. Highfield,
Walter Rocchia,
Nicola Scafuri,
Sauro Succi,
Dieter Kranzlmüller,
Gerald Mathias,
David Wifling,
Yann Donon,
Alberto Di Meglio,
Sofia Vallecorsa,
Heng Ma,
Anda Trifan,
Arvind Ramanathan,
Tom Brettin,
Alexander Partin
, et al. (4 additional authors not shown)
Abstract:
The race to meet the challenges of the global pandemic has served as a reminder that the existing drug discovery process is expensive, inefficient and slow. There is a major bottleneck screening the vast number of potential small molecules to shortlist lead compounds for antiviral drug development. New opportunities to accelerate drug discovery lie at the interface between machine learning methods…
▽ More
The race to meet the challenges of the global pandemic has served as a reminder that the existing drug discovery process is expensive, inefficient and slow. There is a major bottleneck screening the vast number of potential small molecules to shortlist lead compounds for antiviral drug development. New opportunities to accelerate drug discovery lie at the interface between machine learning methods, in this case developed for linear accelerators, and physics-based methods. The two in silico methods, each have their own advantages and limitations which, interestingly, complement each other. Here, we present an innovative infrastructural development that combines both approaches to accelerate drug discovery. The scale of the potential resulting workflow is such that it is dependent on supercomputing to achieve extremely high throughput. We have demonstrated the viability of this workflow for the study of inhibitors for four COVID-19 target proteins and our ability to perform the required large-scale calculations to identify lead antiviral compounds through repurposing on a variety of supercomputers.
△ Less
Submitted 4 September, 2021; v1 submitted 4 March, 2021;
originally announced March 2021.
-
Scalable HPC and AI Infrastructure for COVID-19 Therapeutics
Authors:
Hyungro Lee,
Andre Merzky,
Li Tan,
Mikhail Titov,
Matteo Turilli,
Dario Alfe,
Agastya Bhati,
Alex Brace,
Austin Clyde,
Peter Coveney,
Heng Ma,
Arvind Ramanathan,
Rick Stevens,
Anda Trifan,
Hubertus Van Dam,
Shunzhou Wan,
Sean Wilkinson,
Shantenu Jha
Abstract:
COVID-19 has claimed more 1 million lives and resulted in over 40 million infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. In response, the DOE recently established the Medical Therapeutics project as part of the National Virtual Biotechnology Laboratory, and tasked it with creating the computational infrastructure and methods necessary to advance therapeutics dev…
▽ More
COVID-19 has claimed more 1 million lives and resulted in over 40 million infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. In response, the DOE recently established the Medical Therapeutics project as part of the National Virtual Biotechnology Laboratory, and tasked it with creating the computational infrastructure and methods necessary to advance therapeutics development. We discuss innovations in computational infrastructure and methods that are accelerating and advancing drug design. Specifically, we describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational infrastructure to support these methods at scale. We discuss their implementation and characterize their performance, and highlight science advances that these capabilities have enabled.
△ Less
Submitted 20 October, 2020;
originally announced October 2020.
-
IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads
Authors:
Aymen Al Saadi,
Dario Alfe,
Yadu Babuji,
Agastya Bhati,
Ben Blaiszik,
Thomas Brettin,
Kyle Chard,
Ryan Chard,
Peter Coveney,
Anda Trifan,
Alex Brace,
Austin Clyde,
Ian Foster,
Tom Gibbs,
Shantenu Jha,
Kristopher Keipert,
Thorsten Kurth,
Dieter Kranzlmüller,
Hyungro Lee,
Zhuozhao Li,
Heng Ma,
Andre Merzky,
Gerald Mathias,
Alexander Partin,
Junqi Yin
, et al. (11 additional authors not shown)
Abstract:
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating…
▽ More
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating the entire process. No single methodological approach can achieve the necessary accuracy with required efficiency. Here we describe multiple algorithmic innovations to overcome this fundamental limitation, development and deployment of computational infrastructure at scale integrates multiple artificial intelligence and simulation-based approaches. Three measures of performance are:(i) throughput, the number of ligands per unit time; (ii) scientific performance, the number of effective ligands sampled per unit time and (iii) peak performance, in flop/s. The capabilities outlined here have been used in production for several months as the workhorse of the computational infrastructure to support the capabilities of the US-DOE National Virtual Biotechnology Laboratory in combination with resources from the EU Centre of Excellence in Computational Biomedicine.
△ Less
Submitted 13 October, 2020;
originally announced October 2020.